![]() |
市場調查報告書
商品編碼
1383352
電泳市場到2030年預測:按產品、應用、最終用戶和地區分類的全球分析Electrophoresis Market Forecasts to 2030 - Global Analysis By Product, Application, End User and By Geography |
根據Stratistics MRC的資料,2023年全球電泳市場規模為31億美元,預計2030年將達到52.1億美元,預測期內年複合成長率為7.7%。
可以使用稱為電泳的方法分離蛋白質和核酸。電泳耗材和設備的主要用途是DNA和RNA分析。此外,它還用於生物化學領域,透過電荷、大小和親和性來分離分子。它也用於根據大小、純度和密度等因素分離蛋白質。該技術的易用性使其可用於許多任務,包括疫苗分析、抗體分析、血紅蛋白疾病診斷和藥物品管。
根據 PharmaTimes2018年 12月號報道,2018年前 10 個月,生技部門的創業投資投資額為 135 億美元,超過了2017年創下的 110 億美元的全年紀錄。
在生物技術和生命科學研究中,電泳對於基因組序列測定非常重要。電泳可以分離和分析 DNA 片段,為次世代定序方法的進步鋪平了道路。此外,蛋白質體分析對於幫助了解疾病、藥物開發和生物標記發現非常重要。所有這些領域都增加了對先進電泳系統的需求。
電泳步驟的複雜性是該領域的主要障礙之一。設定和運行準確的電泳實驗需要一定程度的技能。此外,未經專門培訓的研究人員可能難以解釋結果或解決問題,這可能會限制他們進行研究。
高通量電泳系統有一個強大的市場,特別是在蛋白質體學和基因組學等領域。此外,更快、更有效率系統的開發將使研究人員能夠在更短的時間內分析更大的樣本集,大幅增加研究人員的機會。這可能會導致學術研究、製藥和臨床診斷領域的更多採用。
電泳市場面臨的問題是負擔能力。電泳設備、電源以及凝膠和緩衝液等消耗品的初期成本較高,可能妨礙它們在小型實驗室或資源有限的環境中使用。此外,對消耗品的持續需求增加了整體成本,因此為了保持競爭力,製造商必須創新並開發更實惠的解決方案。
電泳市場受到COVID-19大流行的顯著影響。全球供應鏈已中斷,影響了電泳消耗品和設備的可用性。然而,技術在診斷測試開發中發揮的重要作用也受到關注,特別是在 PCR 檢測等測試的快速生產和檢驗中。此外,在全球衛生緊急情況下,疫情凸顯了電泳在疫苗研究和感染疾病研究中的價值,為該產業開闢了新的業務前景。
在預測期內,電泳軟體預計將佔據電泳市場的最大佔有率。在巨量資料時代,這些軟體解決方案對於電泳結果的資料管理、解釋和分析非常重要。它透過確保準確和可重複的結果來提高研究和診斷的有效性,並且在基因組學、蛋白質組學和臨床應用中特別有用。此外,電泳軟體成為電泳市場的支柱,並且由於其自動化資料處理和提供有洞察力的資訊的能力而變得越來越重要。
在電泳市場中,製藥和生物技術公司預計將表現出最高的年複合成長率。這些公司不斷推動對電泳服務和設備的需求,因為他們將電泳用於多種目的,包括生技藥品分析、品管和藥物開發。此外,該市場強勁而穩定的成長部分歸因於對生物製藥的日益關注以及對複雜生物分子準確表徵的需求。他們在研發方面的領先地位使製藥和生物技術公司成為電泳領域創新和市場拓展的主要力量。
北美佔據全球電泳市場最大佔有率。造成這一優勢的因素有很多,包括強大的醫療保健系統、大量的研發投資、慢性病的高盛行率以及生物技術和製藥公司的集中。此外,該地區龐大的市場佔有率也歸功於其強大的學術研究機構和對技術進步的關注。透過積極實施最尖端科技和嚴格的監管要求,我們在北美電泳市場的領導地位得到進一步加強。
在全球電泳市場中,亞太地區的年複合成長率最高。許多因素促成了這種快速成長,包括生物技術和製藥行業的活性化、研究和開發的增加、對精準醫療的重視以及學術和研究機構數量的增加。此外,市場的強勁擴張還得益於該地區醫療基礎設施的不斷擴大以及對尖端診斷技術的需求。因此,亞太地區顯著成長,並成為電泳市場中更重要的參與企業。
According to Stratistics MRC, the Global Electrophoresis Market is accounted for $3.1 billion in 2023 and is expected to reach $5.21 billion by 2030 growing at a CAGR of 7.7% during the forecast period. Proteins and nucleic acids can be separated using an approach called electrophoresis. The primary uses of electrophoresis supplies and equipment are in the analysis of DNA and RNA. Additionally, it is employed in biochemistry to separate molecules according to their charge, size, or affinity. And it is used to separate proteins according to factors such as size, purity, and density. This technique's ease of use makes it useful for a number of tasks, including vaccine analysis, antibody analysis, hemoglobinopathies diagnosis, and drug quality control.
According to PharmaTimes December 2018, 13.5 bn USD venture capital was invested into the biotechnology sector in the first ten months of 2018, beating the previous full-year record of USD 11 bn in 2017.
In biotechnology and life sciences research, electrophoresis is essential for genomic sequencing. It allows DNA fragments to be separated for analysis and opens the door for advancements in next-generation sequencing methods. Furthermore, it is essential for proteomic profiling, which aids in the understanding of diseases, drug development, and biomarker discovery. All of these areas have a greater need for sophisticated electrophoresis systems.
The complicated nature of the procedures involved in electrophoresis is one of the major obstacles in the field. Accurate experiment setup and execution in electrophoresis demand a certain level of skill. Moreover, researchers without specialized training may find it difficult to interpret the results and troubleshoot any issues, which can limit their accessibility.
There is a strong market for high-throughput electrophoresis systems, particularly in areas like proteomics and genomics. Additionally, researcher opportunities can be greatly increased by the development of faster and more efficient systems, which will make it possible to analyze larger sample sets in less time. Increased adoption in academic research, pharmaceuticals, and clinical diagnostics may result from this.
The issue of affordability faces the electrophoresis market. Due to the high initial cost of electrophoresis equipment, power supplies, and consumables like gels and buffers, smaller research labs and environments with limited resources may not be able to use them. Moreover, to remain competitive, manufacturers must innovate and develop more affordable solutions because the continuous need for consumables raises the overall cost.
The market for electrophoresis was greatly affected by the COVID-19 pandemic. The global supply chain was disrupted, which affected the availability of consumables and equipment for electrophoresis. However, it also brought attention to the crucial role that technology plays in the development of diagnostic tests, especially in the quick creation and validation of tests like PCR assays. Furthermore, in the context of international health emergencies, the pandemic highlighted the value of electrophoresis in vaccine research and the study of infectious diseases, opening up new business prospects for the industry.
Over the course of the forecast period, electrophoresis software is expected to hold the largest share in the electrophoresis market. In the big data era, these software solutions are essential for managing, interpreting, and analyzing data from electrophoresis results. They improve the effectiveness of research and diagnostics by guaranteeing precise and repeatable results, which is especially useful in genomics, proteomics, and clinical applications. Moreover, electrophoresis software is becoming a central and increasingly important part of the electrophoresis market because of its capacity to automate data handling and offer insightful information.
In the electrophoresis market, the Pharmaceutical & Biotechnology Companies segment is projected to have the highest CAGR. These businesses constantly drive demand for electrophoresis services and equipment because they use electrophoresis for a variety of purposes, such as biologics analysis, quality control, and drug development. Additionally, the robust and steady growth seen in this market is partly due to the increased focus on biopharmaceuticals and the requirement for accurate characterization of complex biomolecules. Due to their leadership in research and development, pharmaceutical and biotechnology companies are a major force behind innovation and market expansion in the electrophoresis sector.
In the global electrophoresis market, North America holds the largest share. Numerous factors, including a robust healthcare system, large investments in R&D, a high rate of chronic illnesses, and a large concentration of biotechnology and pharmaceutical companies, are responsible for this dominance. Moreover, the substantial market share of the region can be attributed to its strong academic and research institutions, as well as its emphasis on technological advancements. North America's leadership in the electrophoresis market is further cemented by its proactive adoption of cutting-edge techniques and strict regulatory requirements.
In the global electrophoresis market, Asia-Pacific is growing at the highest CAGR. Numerous factors, including the growing biotechnology and pharmaceutical industries, more R&D being done, an increasing emphasis on precision medicine, and an increase in academic and research institutions, are contributing to this rapid growth. Additionally, the strong market expansion is also attributed to the region's expanding healthcare infrastructure and the demand for cutting-edge diagnostic technologies. As a result, Asia-Pacific is growing significantly and is becoming a more significant player in the electrophoresis market.
Some of the key players in Electrophoresis market include: Cleaver Scientific Ltd., Analytik Jena GMBH, Lumex Instruments , Beckman Coulter, Agilent Technologies, Inc., QIAGEN N.V., Sebia Group, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Hoefer, Inc. (Harvard Biosciences), Danaher Corporation, Merck & Co. Inc., Takara Bio, Inc., AES life sciences, Helena Laboratories Corporation, PerkinElmer Inc., SERVA Electrophoresis GmbH, Lonza Group and Shimadzu Corporation.
In August 2023, Collaboration between Beckman Coulter and Fujirebio is expected to lead to multiple new tests for neurodegenerative diseases, including Alzheimer's. The new collaboration, which was announced last month, builds on the supplier relationship between the two companies that has existed for more than 20 years, said Monte Wiltse, president and CEO of Fujirebio Diagnostics.
In April2023, Ohio Lumex Signs Agreement With Mississippi Lime Company (MLC) to Take Over Customer and Technical Services for Breen. MLC grants license to Ohio Lumex to sell and service Breen sulfuric acid dewpoint monitoring technologies. Mississippi Lime Company (MLC), a leading global supplier of high-calcium lime products and technical solutions, has completed an agreement to transfer customer and technical services for its Breen Energy Solutions subsidiary to Ohio Lumex.
In March 2023, Agilent Technologies Inc. today announced a multi-year distribution agreement with Proscia® a leader in digital pathology - to offer a comprehensive digital diagnostic pathology system. Combining Agilent's trusted pathology staining solutions with Proscia's Concentriq® Dx enterprise pathology platform will empower pathology labs to transform diagnostic efficiency and quality to improve patient health outcomes.